The recommendation comes from a cooperative study involving 1205 men, said lead author Padraig Warde, MBChB, from the University of Toronto's Princess Margaret Hospital in Ontario. At 7 years, 74% of ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That ...

Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...